Relevance of allosteric conformations and homocarnosine concentration on carnosinase activity

Autor: Verena Peters, Georg F. Hoffmann, Katja Adelmann, Erwin E. W. Jansen, Hannes Koeppel, Cornelis Jakobs, Moustafa Kebbewar, Matthias Mack, Bart Janssen, Dirk Frey, Johannes Zschocke, Eva Riedl, Kristina Klingbeil, Benito A. Yard
Přispěvatelé: Laboratory Medicine, NCA - Childhood White Matter Diseases
Rok vydání: 2010
Předmět:
Zdroj: Amino Acids, 38(5), 1607-1615. Springer Wien
Peters, V, Kebbewar, M, Jansen, E E W, Jakobs, C, Riedl, E, Koeppel, H, Frey, D, Adelmann, K, Klingbeil, K, Mack, M, Hoffmann, G F, Janssen, B, Zschocke, J & Yard, B A 2010, ' Relevance of allosteric conformations and homocarnosine concentration on carnosinase activity ', Amino Acids, vol. 38, no. 5, pp. 1607-1615 . https://doi.org/10.1007/s00726-009-0367-z
ISSN: 0939-4451
DOI: 10.1007/s00726-009-0367-z
Popis: Activity of carnosinase (CN1), the only dipeptidase with substrate specificity for carnosine or homocarnosine, varies greatly between individuals but increases clearly and significantly with age. Surprisingly, the lower CN1 activity in children is not reflected by differences in CN1 protein concentrations. CN1 is present in different allosteric conformations in children and adults since all sera obtained from children but not from adults were positive in ELISA and addition of DTT to the latter sera increased OD450 values. There was no quantitative difference in the amount of monomeric CN1 between children and adults. Further, CN1 activity was dose dependently inhibited by homocarnosine. Addition of 80 microM homocarnosine lowered V (max) for carnosine from 440 to 356 pmol/min/microg and increased K (m) from 175 to 210 microM. The estimated K (i) for homocarnosine was higher (240 microM). Homocarnosine inhibits carnosine degradation and high homocarnosine concentrations in cerebrospinal fluid (CSF) may explain the lower carnosine degradation in CSF compared to serum. Because CN1 is implicated in the susceptibility for diabetic nephropathy (DN), our findings may have clinical implications for the treatment of diabetic patients with a high risk to develop DN. Homocarnosine treatment can be expected to reduce CN1 activity toward carnosine, resulting in higher carnosine levels.
Databáze: OpenAIRE